market research report : anti diabetic pharmaceuticals market in india 2012

Insert Cover Image using Slide Master View

Do not distort

Anti-Diabetic Pharmaceuticals Market - India

March 2012

2ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

SAMPLE

ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

Drivers:

� Increase in the number of diabetic

patients

� Introduction of newer and better drugs

� Increasing aging population

�Comprehensive health insurances

policies covering diabetes

Drug

Regulation and

Patents

� Global Market of Anti-diabetic pharmaceuticals is expected to growth at a CAGR of X% for 2010 – 2015 period

� Anti-diabetic pharmaceuticals market in India is valued at INR xx units in 20--

� Market is expected to grow at a CAGR of m% from 20-- to 20--

� Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology

Challenges:� Price regulation in insulin market

� Use of complementary and alternative medicines

� Maintainence of healthy lifestyle to avoid diabetes

� Phases of clinical trial

� Approval and licensing of drugs

� Patents

Competition

Drivers and

Challenges

Market

Executive Summary

Company GCompany HCompany ICompany J

Company ACompany BCompany CCompany DCompany ECompany F

Private CompaniesPublic Companies


•Introduction

•Market Overview

•Drivers & Challenges

•Government Initiatives

•Market Value Chain, Regulation and Patents

•Competition

•Strategic recommendation


SAMPLE

India’s diabetes market is poised to grow over the coming

years

Indian Market – Overview Market Size and Growth

Market Segmentation

Source:

0 5 10 15 20 25 30 35

h

gastro g

pain f

respiratory e

CNS d

CVS c

diabetes b

oncology a%

anti-infectives

Growth in therapeutic segments(2010)

X 1

Y 1

X 2Y 2

Insulin

Drugs

0

10

20

30

40

INR bn

A

y%

20--e

F

20--e

E

20--e

D

20--e

C

20--e

B

20--

• India is considered to be one of the most lucrative diabetes markets in the world

• Anti-diabetics represent the second fastest growing therapeutic segment among all the segments ,after oncology

• Market is expected to grow from INR A bn to INR F bn in 20--, at a CAGR of y%

• Biguanides, Gliclazide, Gliclazide with metformine, Rosiglitazone and Pioglitazone are the top selling drugs in Indian market

• Human Mixard 30/70 is the largest selling insulin in Indian market� It showed largest growth among the top 10 brands in Indian

Pharmaceutical market


Drivers & Challenges

Increase in health insurances

Increasing aging population

Introduction of newer and better

drugs

Increase in the number of diabetic

patients

Drivers

Maintainence of healthy lifestyle to

avoid diabetes

Competition from complementary and

alternative medicines

Price regulation in insulin market

Challenges


SAMPLE

Various initiatives taken by the government is providing a

boost to this market

• ICDC ,registered under Planning Commission, Government of India, is the only organisation in India providing doorstep diabetes care

• ICDC implements National Doorstep Diabetes Identification and follow-up programme through Grass Root Level NGOs all over India

• ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help them to control diabetes and live without any complications

• ICDC provides free glucometer and 100 Strips to the NGOs to start identifying the diabetes patients even in villages

• ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India as in the case of family planning insurance scheme

• National Programme for prevention and Control of Diabetes, Cardiovascular diseases and Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and early management of diabetes

• It is already being implemented in 100 most backward and remote districts spread across 21 states

• Indian Government plans to extend this programme to all the 650 districts of the country under the 12th

five year plan

• National Rural Health Mission is providing services for diabetes care in rural India

• Seeks to provide effective healthcare to rural population throughout the country with special

focus on 18 states

Indian Council for

Diabetic Care

NPCDCS

NRHM

Source:


SAMPLE

Major Private Companies - Summary

C

B

A

PAT

1,000

0

-1,000

-2,000

-3,000

-4,000

-5,000

-6,000

-7,000

-8,000

-9,000

-10,000

-11,000 Revenue

3,500,0003,000,0002,500,0002,000,0001,500,0001,000,000500,0000-500,000

Size of the Bubble represents Total Assets

in INR XX

CBA


SAMPLE

Public: Domestic Company – A Company (1/3)

Key People

Products and Services

Company Information Offices and Centres – India

NNNStock Exchange

Corporate AddressX Road

Bangalore

Tel No. +91 xx xxxxx xxxxx

Fax No. +91 xx xxxxx xxxxx

Website www.ppp.com

Year of Incorporation 19--

Ticker Symbol xxxxxx

Name Designation

Person M Founder

Person N CFO

Person O Head

Person Q President

City A Products and ServicesHead Office

Source:

Category Products/Services

Pharmaceutical

CVD, CNS, respiratory, dermatology,

orthopedics, nutritional, urology, anti-

infectives

Molecule

Development

Infectious diseases, metabolic diseases,

inflammatory/respiratory diseases, and

oncology


SAMPLE

Source:

Key Ratios

Financial Summary


• The company incurred a net loss of INR xx mn in FY 20--, as

compared to net profit of INR yy mn in FY 20--

• The company reported total income of INR xx bn in FY 20--,

registering an increase of yy per cent over FY 20--

• The company earned an operating margin of x per cent in FY 20-- a

decrease of y percentage points over FY 20--

• The company reported debt to equity ratio of x in FY 20--, an

increase of y per cent over FY 20--

Financial Summary

Profit / Loss

Revenue

0

-m

Revenue

INR mn

Profit

INR mn

p

n

t

s

r

q

0

20--

t

p

20--

s

o

20--

r

n

20--

q

m

Indicators Present Value

Market Capitalization (INR) X mn

Total Enterprise Value (INR) Y mn

EPS (INR) Z mn

PE Ratio (Absolute) A

Particulars y-o-y change 20-- 20-- 20-- 20--

Profitability Ratios

Operating Margin

Net Margin

Profit Before Tax Margin

Return on Equity

Return on Capital Employed

Return on Working Capital

Return on Assets

Return on Fixed Assets

Cost Ratios

Operating costs (% of Sales)

Administration costs (% of

Sales)

Interest costs (% of Sales)

Liquidity Ratios

Current Ratio

Cash Ratio

Leverage Ratios

Debt to Equity Ratio

Debt to Capital Ratio

Interest Coverage Ratio

Efficiency Ratios

Fixed Asset Turnover

Asset Turnover

Current Asset Turnover

Working Capital Turnover

Capital Employed Turnover

Improved Decline

Financial Snapshot


SAMPLE


y

x

20--

z y

x

20--

z y

x

20--

zy

x

20--

z

onm

Key Business Segments

20--

z

y

x

20--

z

y

x

20--

z

y

x

20--

z

y

x

x y z

Key Geographic Segments

Source:

Key Recent Developments

• Launched Drug M for the treatment of diabetes

• Also manufactures Insulin N under its Diabetes management segmentDiabetes Management

Description News

Overview• Company A is an integrated research based company that produces a wide range of generic medicines

• Serves customers in over 100 countries with manufacturing facilities in several countries

Key Initiatives• Is making consistent effort for continual improvement in rural areas with respect to accessibility of

medicines


Thank you for the attention

About Netscribes

Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &

business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true

value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth

objectives.

The Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare

Industry Series.

For more detailed information or customized research requirements please contact:

Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,

Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the

sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.

Tamojit Roy

E-Mail: [email protected]

Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on “hot” industries in India and other

emerging markets. Track our new releases and major updates in these industries on

market research report : anti diabetic pharmaceuticals market in india 2012

Health & Medicine